Zahraa Maitham AL-Khateeb
Department of Chemistry and Biochemistry, College of Medicine, Mustansiriyah University, Iraq, pharmacistzahraaalkhateeb@gmail.com
Prof. Dr. Sura A. Abdulsattar
Department of Chemistry and Biochemistry, College of Medicine, Mustansiriyah University, Iraq, esamnoori61@gmail.com
Assist. Prof. Dr. Isam N.Salman
Diabetes and endocrine disease. College of Medicine, Mustansiriyah University, Iraq. Emails: surasci@uomustansiriyah.edu.iq
Abstract
Background: High mobility group B1 is associated with central ischemic damage, being released into the extracellular space after ischemic insult where it promotes neuroinflammation like neuropathy which represent a signficant complication of diabetes and it is difficult to treat. Objective: is to investigate the changes of serum levels of High Mobility Group Box-1 Protein (HMGB-1) and its association with the incidence of developing neuropathic complications among diabetic patients. Material & Methods: A 30 patients with diabetic peripheral neuropathy was included with another 30 patients with Diabetes Mellitus type 2 without complications and a 30 healthy subject as control group both sex-aged matched with the patients groups. This study included the measurement of serum high mobility group box -1 (HMGB-1) by ELISA technique in addition to HbA1c by turbidimetric immunoassay technology, Fasting blood sugar and finally Lipid profile (Total cholesterol, LDL, VLDL, HDL and Triglycerides) were measured by spectrophotometer. Results: Analyzing the current data of samples (n=90) showed that the comparison between serum level of HMGB-1 was significant. The mean of HMGB_1 for NPDM (689.08± 104.63) was significantly higher than both for Non-NPDM (354.97± 137.56), p < 0.001 and for control (312.91± 100.66), (p < 0.001).Also serum levels of (Total Cholesterol, TG, LDL, VLDL) of NPDM patients were significantly higher (p<0.001) than both Non-NPDM and control groups. We conclude that serum level of HMGB-1 can be used as predictor marker of neuropathy complication of type 2 diabetes.
Keywords:
Serum, Box-1, Diabetic Peripheral Neuropathy
References
1. Feldman, E.L., Callaghan, B.C., Pop-Busui, R., Zochodne, D.W., Wright, D.E., Bennett, D.L., Bril, V., Russell, J.W. and Viswanathan, V., 2019. Diabetic neuropathy. Nature reviews Disease primers, 5(1), pp.1-18.
2. Artasensi, A., Pedretti, A., Vistoli, G. and Fumagalli, L., 2020. Type 2 diabetes mellitus: A review of multi-target drugs. Molecules, 25(8), p.1987.
3. Wang, Y., Zhong, J., Zhang, X., Liu, Z., Yang, Y., Gong, Q. and Ren, B., 2016. The role of HMGB1 in the pathogenesis of type 2 diabetes. Journal of diabetes research, 2016.
4. Goodwin, G.H., Sanders, C. and Johns, E.W., 1973. A new group of chromatin‐associated proteins with a high content of acidic and basic amino acids. European Journal of Biochemistry, 38(1), pp.14-19.
5. Biscetti, F., Rando, M.M., Nardella, E., Cecchini, A.L., Pecorini, G., Landolfi, R. and Flex, A., 2019. High mobility group box-1 and diabetes mellitus complications: state of the art and future perspectives. International journal of molecular sciences, 20(24), p.6258.
6. Lu, B.; Antoine, D.J.; Kwan, K.; Lundbäck, P.; Wähämaa, H.; Schierbeck, H.; Robinson, M.; Van Zoelen, M.A.D.; Yang, H.; Li, J.; et al. JAK/STAT1 signaling promotes HMGB1 hyperacetylation and nuclear translocation. Proc. Natl. Acad. Sci. USA 2014, 111, 3068–3073.
7. Wu, H.; Li, R.; Wei, Z.H.; Zhang, X.L.; Chen, J.Z.; Dai, Q.; Xie, J.; Xu, B. Diabetes-Induced Oxidative Stress in Endothelial Progenitor Cells May Be Sustained by a Positive Feedback Loop Involving High Mobility Group Box-1. Oxid. Med. Cell. Longev. 2016, 2016,
8. Dasu, M.R., Devaraj, S., Park, S. and Jialal, I., 2010. Increased toll-like receptor (TLR) activation and TLR ligands in recently diagnosed type 2 diabetic subjects. Diabetes care, 33(4), pp.861-868.
9. Škrha Jr, J., Kalousova, M., Švarcová, J., Muravska, A., Kvasnička, J., Landova, L., Zima, T. and Škrha, J., 2012. Relationship of soluble RAGE and RAGE ligands HMGB1 and EN-RAGE to endothelial dysfunction in type 1 and type 2 diabetes mellitus. Experimental and clinical endocrinology & diabetes, 120(05), pp.277-281.
10. Bianchi, M.E. and Manfredi, A.A., 2007. High‐mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunological reviews, 220(1), pp.35-46.
11. Raucci, A., Palumbo, R. and Bianchi, M.E., 2007. HMGB1: a signal of necrosis. Autoimmunity, 40(4), pp.285-289.
12. Vikrum Thakur,., Sadanandan, J. and Chattopadhyay, M., 2020. High-mobility group box 1 protein signaling in painful diabetic neuropathy. International journal of molecular sciences, 21(3), p.881.
13. Andersson, U., Wang, H., Palmblad, K., Aveberger, A.C., Bloom, O., Erlandsson-Harris, H., Janson, A., Kokkola, R., Zhang, M., Yang, H. and Tracey, K.J., 2000. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. Journal of Experimental Medicine, 192(4), pp.565-570
14. Cai, Z., Yang, Y., & Zhang, J. (2021). A systematic review and meta-analysis of the serum lipid profile in prediction of diabetic neuropathy. Scientific reports, 11(1), 499. https://doi.org/10.1038/s41598-020-79276-0
